Clinical trial

Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics

NCT02230189

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Segmental airway allergen challenge Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Bronchoscopy Find medicine records · Find other trials using this name

DIAGNOSTIC_TEST · Unmapped registry intervention Methacholine challenge test Find medicine records · Find other trials using this name

DIAGNOSTIC_TEST · Unmapped registry intervention Spirometry Find medicine records · Find other trials using this name

DIAGNOSTIC_TEST · Unmapped registry intervention Allergen skin prick test Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-03-01

PhasePHASE2

Conditions

Asthmaverified · MONDO: asthma

Interventions

Segmental airway allergen challengeBIOLOGICAL

BronchoscopyPROCEDURE

Methacholine challenge testDIAGNOSTIC_TEST

SpirometryDIAGNOSTIC_TEST

Allergen skin prick testDIAGNOSTIC_TEST

Sponsors & collaborators

Prescott Woodrufflead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

Mapped research locations

San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02230189 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.